Summary

KEY FINDINGS
The North America retinal imaging devices market size is valued at $1,643.22 million as of 2026 and is expected to reach $2,909.75 million by 2034, progressing with a CAGR of 7.40% during the forecast years, 2026-2034.

MARKET INSIGHTS
North America dominates the global retinal imaging devices market due to advanced healthcare infrastructure, substantial research and development investments, and high adoption rates of cutting-edge ophthalmic diagnostic equipment. The region benefits from well-established reimbursement frameworks that facilitate access to optical coherence tomography systems and fundus cameras across diverse care settings.
Moreover, the escalating prevalence of diabetes and aging demographics creates a persistent demand for retinal screening technologies. According to the CDC's Vision and Eye Health Surveillance System, approximately 9.6 million Americans lived with diabetic retinopathy in 2021, representing 26.4% of those with diabetes. Furthermore, projections indicate this figure will reach 14.7 million by 2050.
Additionally, government initiatives promoting preventive eye care and teleophthalmology programs expand screening accessibility in underserved rural communities. Leading manufacturers like Carl Zeiss Meditec, Topcon Corporation, and Heidelberg Engineering maintain significant operational presence throughout North America, driving continuous innovation in retinal diagnostic imaging technology.

REGIONAL ANALYSIS
The North America retinal imaging devices market growth assessment includes the analysis of the United States and Canada.
The United States represents the largest market for retinal imaging equipment within North America, propelled by high healthcare expenditure, extensive ophthalmology infrastructure, and favorable regulatory environments. The U.S. healthcare system encompasses thousands of hospitals, specialty eye clinics, and diagnostic centers equipped with advanced retinal imaging cameras and OCT angiography systems.
Medicare and private insurance coverage facilitate widespread adoption of these diagnostic technologies for diabetic retinopathy screening and age-related macular degeneration monitoring. According to research published in JAMA Ophthalmology, diabetic retinopathy prevalence among those with diabetes ranged from 20.8% in Nevada to 31.3% in Massachusetts, highlighting significant geographic variation. This disparity creates opportunities for targeted deployment of portable retinal imaging devices in underserved regions.
Moreover, the United States leads in artificial intelligence integration for automated retinal image analysis. The FDA has approved multiple autonomous AI systems, including IDx-DR and EyeArt, enabling primary care physicians to conduct diabetic retinopathy screenings without specialist oversight. According to recent implementations, approximately 198 AI-equipped cameras have been deployed across five U.S. health systems since 2020, covering roughly 151,000 diabetic patients.
Additionally, teleophthalmology programs connecting rural screening sites with urban ophthalmologists expand access to retinal diagnostic services. Veterans Affairs facilities, Indian Health Service clinics, and federally qualified health centers increasingly adopt connected retinal imaging devices to address ophthalmologist workforce shortages. Consequently, the U.S. market presents substantial growth opportunities for vendors offering portable, AI-enabled retinal imaging systems with telehealth capabilities.
Canada exhibits steady growth in the retinal imaging devices market, driven by universal healthcare coverage, increasing diabetes prevalence, and government support for preventive eye care programs. Over four million Canadians have been diagnosed with diabetes, with this figure projected to exceed five million by 2033.
Provincial health systems increasingly invest in tele-ophthalmology infrastructure to serve remote and northern communities, particularly Indigenous populations experiencing disproportionately high diabetes rates. Aligning with this, Manitoba's teleophthalmology screening program exemplifies successful implementation, with trained nurses conducting retinal examinations using portable fundus cameras in rural settings.
These initiatives create demand for durable, user-friendly retinal imaging equipment suitable for non-specialist operators. Furthermore, Canadian healthcare providers prioritize cost-effective solutions that balance diagnostic accuracy with total ownership expenses, presenting opportunities for vendors offering competitively priced optical coherence tomography devices with comprehensive service agreements.

SEGMENTATION ANALYSIS
The North America retinal imaging devices market is segmented into device, application, and indication. The device segment is further categorized into optical coherence tomography (OCT) devices (spectral-domain OCT, swept-source OCT, handheld OCT), fluorescein angiography devices, fundus cameras (mydriatic fundus cameras, non-mydriatic fundus cameras, hybrid fundus cameras, ROP fundus cameras), retinal ultrasound imaging systems (ophthalmic A-scan ultrasound, ophthalmic B-scan ultrasound, ophthalmic ultrasound biomicroscopes, ophthalmic pachymeters), ultra widefield retinal imaging devices, widefield retinal imaging devices, and other devices.
Optical coherence tomography (OCT) devices command the dominant position in North America's retinal imaging equipment market due to their superior diagnostic capabilities and widespread clinical adoption. These sophisticated systems utilize low-coherence interferometry to generate high-resolution cross-sectional images of retinal structures with unprecedented detail, enabling early detection of diabetic macular edema, glaucomatous optic nerve changes, and age-related macular degeneration.
Spectral-domain OCT technology currently represents the clinical standard, offering rapid scanning speeds up to 100,000 A-scans per second while maintaining excellent image quality. Tertiary care hospitals, academic medical centers, and retina specialty practices extensively utilize OCT systems for both initial diagnosis and ongoing treatment monitoring. Consequently, declining equipment costs and expanding Medicare reimbursement codes for OCT examinations facilitate adoption in community ophthalmology practices and optometry clinics.
Vendors offering integrated OCT-angiography capabilities without contrast dye injection gain competitive advantages, as these systems provide comprehensive vascular assessment alongside structural imaging. Furthermore, the segment benefits from continuous technological innovation, with manufacturers introducing artificial intelligence-powered analysis software that automates measurement and progression detection, thereby reducing interpretation time while improving diagnostic consistency across diverse clinical settings.

COMPETITIVE INSIGHTS
Some of the top players operating in the North America retinal imaging devices market include Carl Zeiss Meditec AG, Topcon Corporation, Heidelberg Engineering GmbH, Canon Inc, etc.
Carl Zeiss Meditec AG stands as a leading manufacturer of ophthalmic diagnostic and surgical equipment, headquartered in Jena, Germany, with substantial North American operations. The company specializes in advanced retinal imaging technologies, particularly its flagship CIRRUS OCT platform, which dominates the spectral-domain optical coherence tomography segment. Zeiss's product portfolio encompasses comprehensive solutions, including fundus cameras, OCT-angiography systems, surgical microscopes, and integrated diagnostic workstations for comprehensive eye examinations.
Additionally, the company provides AngioPlex OCT-A technology that visualizes retinal vasculature without invasive dye injection. Zeiss serves diverse customer segments, including hospital ophthalmology departments, retina specialty practices, comprehensive ophthalmology clinics, and optometry offices throughout North America. The company's business model emphasizes premium product positioning, extensive customer support networks, comprehensive training programs, and ongoing software upgrades that maintain installed base loyalty while driving recurring revenue streams from service contracts and disposable components.

COMPANY PROFILES
1. CANON INC
2. CARL ZEISS MEDITEC AG
3. ESCALON MEDICAL CORP
4. FORUS HEALTH PVT LTD
5. HEIDELBERG ENGINEERING GMBH
6. KOWA COMPANY LTD
7. NIDEK CO LTD
8. OPTOS PLC
9. SANTEC CORPORATION
10. TOPCON CORPORATION

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & FORECAST
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. WIDESPREAD ADOPTION OF FUNDUS CAMERAS AND OCT SYSTEMS IS DRIVEN BY RISING SCREENING NEEDS FOR DIABETIC RETINOPATHY AND AGE-RELATED MACULAR DEGENERATION
2.5.2. HOSPITALS AND DIAGNOSTIC CLINICS ACCOUNT FOR THE LARGEST SHARE DUE TO HIGH PATIENT FOOTFALL AND INTEGRATED OPHTHALMOLOGY SETUPS
2.5.3. PORTABLE AND HANDHELD RETINAL IMAGING DEVICES ARE GAINING TRACTION IN RURAL AND PRIMARY CARE SETTINGS
2.5.4. DEVELOPED MARKETS DOMINATE REVENUE WHILE EMERGING ECONOMIES SHOW FASTER VOLUME GROWTH
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING GLOBAL PREVALENCE OF DIABETES AND AGING POPULATION IS EXPANDING THE AT-RISK PATIENT BASE
3.1.2. GOVERNMENT AND NGO LED EYE SCREENING PROGRAMS ARE BOOSTING DEMAND FOR RETINAL DIAGNOSTIC TOOLS
3.1.3. TECHNOLOGICAL ADVANCES IN OCT AI ASSISTED DIAGNOSTICS AND IMAGE QUALITY ARE IMPROVING CLINICAL OUTCOMES
3.1.4. RISING AWARENESS AMONG PHYSICIANS AND PATIENTS ABOUT EARLY DETECTION OF RETINAL DISORDERS IS SUPPORTING MARKET EXPANSION
3.2. KEY RESTRAINTS
3.2.1. HIGH CAPITAL COST OF ADVANCED RETINAL IMAGING SYSTEMS LIMITS ADOPTION IN SMALL CLINICS
3.2.2. LACK OF TRAINED OPHTHALMOLOGISTS AND TECHNICIANS CONSTRAINS EFFECTIVE UTILIZATION IN LOW-INCOME REGIONS
3.2.3. REIMBURSEMENT VARIABILITY ACROSS COUNTRIES AFFECTS PURCHASE DECISIONS BY HEALTHCARE PROVIDERS
3.2.4. REGULATORY APPROVAL AND DEVICE CERTIFICATION REQUIREMENTS CAN DELAY PRODUCT COMMERCIALIZATION
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. INTEGRATION OF ARTIFICIAL INTELLIGENCE FOR AUTOMATED RETINAL IMAGE ANALYSIS IS ACCELERATING
4.1.2. SHIFT TOWARD NON-MYDRIATIC AND PATIENT-FRIENDLY IMAGING SYSTEMS IS IMPROVING SCREENING COMPLIANCE
4.1.3. GROWING USE OF TELE OPHTHALMOLOGY IS DRIVING DEMAND FOR CONNECTED RETINAL IMAGING DEVICES
4.1.4. MANUFACTURERS ARE FOCUSING ON COMPACT AND PORTABLE DESIGNS TO EXPAND POINT OF CARE APPLICATIONS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. RAW MATERIAL SUPPLIERS
4.6.2. OPTICAL COMPONENTS
4.6.3. DEVICE MANUFACTURING
4.6.4. SOFTWARE DEVELOPMENT
4.6.5. DISTRIBUTION CHANNELS
4.6.6. HOSPITALS AND CLINICS
4.6.7. AFTERSALES SUPPORT
4.7. KEY BUYING CRITERIA
4.7.1. IMAGE RESOLUTION
4.7.2. CLINICAL ACCURACY
4.7.3. EASE OF USE
4.7.4. TOTAL COST OWNERSHIP
4.8. REGULATORY FRAMEWORK
5. RETINAL IMAGING DEVICES MARKET BY DEVICE
5.1. OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES
5.1.1. SPECTRAL-DOMAIN OCT (SD-OCT)
5.1.2. SWEPT-SOURCE OCT (SS-OCT)
5.1.3. HANDHELD OCT
5.2. FLUORESCEIN ANGIOGRAPHY DEVICES
5.3. FUNDUS CAMERAS
5.3.1. MYDRIATIC FUNDUS CAMERAS
5.3.2. NON-MYDRIATIC FUNDUS CAMERAS
5.3.3. HYBRID FUNDUS CAMERAS
5.3.4. ROP FUNDUS CAMERAS
5.4. RETINAL ULTRASOUND IMAGING SYSTEMS
5.4.1. OPHTHALMIC A-SCAN ULTRASOUND
5.4.2. OPHTHALMIC B-SCAN ULTRASOUND
5.4.3. OPHTHALMIC ULTRASOUND BIOMICROSCOPES
5.4.4. OPHTHALMIC PACHYMETERS
5.5. ULTRA WIDEFIELD RETINAL IMAGING DEVICES
5.6. WIDEFIELD RETINAL IMAGING DEVICES
5.7. OTHER DEVICES
6. RETINAL IMAGING DEVICES MARKET BY APPLICATION
6.1. DISEASE DIAGNOSIS
6.2. TREATMENT MONITORING
6.3. RESEARCH AND DEVELOPMENT
7. RETINAL IMAGING DEVICES MARKET BY INDICATION
7.1. DIABETIC RETINOPATHY
7.2. AGE-RELATED MACULAR DEGENERATION (AMD)
7.3. GLAUCOMA
7.4. RETINAL VEIN OCCLUSION
7.5. OTHER INDICATIONS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA MARKET DRIVERS
8.1.3. NORTH AMERICA MARKET CHALLENGES
8.1.4. KEY PLAYERS IN NORTH AMERICA RETINAL IMAGING DEVICES MARKET
8.1.5. COUNTRY ANALYSIS
8.1.5.1. UNITED STATES
8.1.5.1.1. UNITED STATES MARKET SIZE & OPPORTUNITIES
8.1.5.2. CANADA
8.1.5.2.1. CANADA MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. CANON INC
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCT LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. CARL ZEISS MEDITEC AG
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCT LIST
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. ESCALON MEDICAL CORP
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCT LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. FORUS HEALTH PVT LTD
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCT LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. HEIDELBERG ENGINEERING GMBH
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCT LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. KOWA COMPANY LTD
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCT LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. NIDEK CO LTD
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. PRODUCT LIST
9.2.7.3. STRENGTHS & CHALLENGES
9.2.8. OPTOS PLC
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. PRODUCT LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. SANTEC CORPORATION
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. PRODUCT LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. TOPCON CORPORATION
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. PRODUCT LIST
9.2.10.3. STRENGTHS & CHALLENGES


LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - RETINAL IMAGING DEVICES
TABLE 2: MARKET BY DEVICE, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 3: MARKET BY DEVICE, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 4: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 5: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 6: MARKET BY FUNDUS CAMERAS, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 7: MARKET BY FUNDUS CAMERAS, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 8 MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 9: MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 10: MARKET BY APPLICATION, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 11: MARKET BY APPLICATION, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 12: MARKET BY INDICATION, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 13: MARKET BY INDICATION, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 14: NORTH AMERICA MARKET, COUNTRY ANALYSIS, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 15: NORTH AMERICA MARKET, COUNTRY ANALYSIS, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 16: KEY PLAYERS OPERATING IN THE NORTH AMERICAN MARKET
TABLE 17: LIST OF MERGERS & ACQUISITIONS
TABLE 18: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 19: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 20: LIST OF BUSINESS EXPANSIONS & DIVESTITURES


LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: SEGMENT GROWTH POTENTIAL, BY DEVICE, IN 2025
FIGURE 9: OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 10: SEGMENT GROWTH POTENTIAL, BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, IN 2025
FIGURE 11: SPECTRAL-DOMAIN OCT (SD-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 12: SWEPT-SOURCE OCT (SS-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 13: HANDHELD OCT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 14: FLUORESCEIN ANGIOGRAPHY DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 15: FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 16: SEGMENT GROWTH POTENTIAL, BY FUNDUS CAMERAS, IN 2025
FIGURE 17: MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 18: NON-MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 19: HYBRID FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 20: ROP FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 21: RETINAL ULTRASOUND IMAGING SYSTEMS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 22: SEGMENT GROWTH POTENTIAL, BY RETINAL ULTRASOUND IMAGING SYSTEMS, IN 2025
FIGURE 23: OPHTHALMIC A-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 24: OPHTHALMIC B-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 25: OPHTHALMIC ULTRASOUND BIOMICROSCOPES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 26: OPHTHALMIC PACHYMETERS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 27: ULTRA WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 28: WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 29: OTHER DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 30: SEGMENT GROWTH POTENTIAL, BY APPLICATION, IN 2025
FIGURE 31: DISEASE DIAGNOSIS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 32: TREATMENT MONITORING MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 33: RESEARCH AND DEVELOPMENT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 34: SEGMENT GROWTH POTENTIAL, BY INDICATION, IN 2025
FIGURE 38: DIABETIC RETINOPATHY MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 35: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 36: GLAUCOMA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 37: RETINAL VEIN OCCLUSION MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 38: OTHER INDICATIONS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 39: NORTH AMERICA RETINAL IMAGING DEVICES MARKET, COUNTRY OUTLOOK, 2025 & 2034 (IN %)
FIGURE 40: UNITED STATES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 41: CANADA MARKET SIZE, 2026-2034 (IN $ MILLION)